File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines

TitleSirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines
Authors
Issue Date2007
Citation
Transplantation, 2007, v. 83 n. 12, p. 1635-1638 How to Cite?
AbstractPresently, sirolimus (rapamycin) is used as both induction and maintenance immunosuppression in solid organ transplants, including whole pancreas and kidney, and islet transplantation. Sirolimus has been suggested to have deleterious effects on islet β-cell and renal function. We investigated the effect of sirolimus on the viability of islets, podocytes, and renal tubular cells. Sirolimus reduced the viability of islets and HK-2 human proximal renal tubular cells in vitro. This toxic effect was associated with a reduction of vascular endothelial growth factor (VEGF) release by islets but not the proximal tubular cells. Sirolimus reduced both viability and VEGF production by murine β-cells, and blockade of VEGF-164 was associated with a reduction in viability. Transfection of murine islets with adenoviral VEGF-165 improved islet viability. These data are consistent with the hypothesis that sirolimus is toxic to islets and β-cells by blockade of VEGF-mediated survival pathways. © 2007 Lippincott Williams & Wilkins, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/195450
ISSN
2015 Impact Factor: 3.69
2015 SCImago Journal Rankings: 1.699
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLaugharne, M-
dc.contributor.authorCross, S-
dc.contributor.authorRichards, S-
dc.contributor.authorDawson, C-
dc.contributor.authorIlchyshyn, L-
dc.contributor.authorSaleem, M-
dc.contributor.authorMathieson, P-
dc.contributor.authorSmith, R-
dc.date.accessioned2014-02-28T06:12:10Z-
dc.date.available2014-02-28T06:12:10Z-
dc.date.issued2007-
dc.identifier.citationTransplantation, 2007, v. 83 n. 12, p. 1635-1638-
dc.identifier.issn0041-1337-
dc.identifier.urihttp://hdl.handle.net/10722/195450-
dc.description.abstractPresently, sirolimus (rapamycin) is used as both induction and maintenance immunosuppression in solid organ transplants, including whole pancreas and kidney, and islet transplantation. Sirolimus has been suggested to have deleterious effects on islet β-cell and renal function. We investigated the effect of sirolimus on the viability of islets, podocytes, and renal tubular cells. Sirolimus reduced the viability of islets and HK-2 human proximal renal tubular cells in vitro. This toxic effect was associated with a reduction of vascular endothelial growth factor (VEGF) release by islets but not the proximal tubular cells. Sirolimus reduced both viability and VEGF production by murine β-cells, and blockade of VEGF-164 was associated with a reduction in viability. Transfection of murine islets with adenoviral VEGF-165 improved islet viability. These data are consistent with the hypothesis that sirolimus is toxic to islets and β-cells by blockade of VEGF-mediated survival pathways. © 2007 Lippincott Williams & Wilkins, Inc.-
dc.languageeng-
dc.relation.ispartofTransplantation-
dc.titleSirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.tp.0000266555.06635.bf-
dc.identifier.pmid17589348-
dc.identifier.scopuseid_2-s2.0-34250815070-
dc.identifier.volume83-
dc.identifier.issue12-
dc.identifier.spage1635-
dc.identifier.epage1638-
dc.identifier.isiWOS:000247578200018-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats